Skip to main content
TipRanks
Go Ultimate75% OFF

Shilpa Medicare Limited (SHILPAMED) AI Stock Analysis

3 Followers
IN:SHILPAMED

Shilpa Medicare Limited

(NSE:SHILPAMED)

Select Model
Rating:71.4Outperform
Price Target:INR 1,015.00â–²(10.69% Upside)
Action:reiterated
Date:09/19/26

The overall score reflects a company in a solid recovery phase: revenues and profits are growing with improving margins and moderate leverage, which is the primary driver of the rating. Strong technical momentum and a clear uptrend further support the score, signaling positive market sentiment. However, the rich valuation and history of negative free cash flow temper the upside, keeping the stock in an attractive but not top‑tier range.

Positive Factors
Revenue and Margin RecoveryThe FY2026 recovery shows stronger operating performance, combining renewed revenue growth with substantially better profitability. If these margins are maintained, the company should have greater capacity to fund research, commercial expansion, and operations while strengthening earnings resilience over the next several quarters.
Negative Factors
Persistent Negative Free Cash FlowPersistent negative free cash flow means reported earnings are not yet translating into surplus cash after investment needs. This can constrain internally funded expansion, increase reliance on financing, and leave less flexibility if working-capital or development requirements remain elevated.

Shilpa Medicare Limited (SHILPAMED) vs. iShares MSCI India ETF (INDA)

-50%0%50%100%150%200%250%IN:SHILPAMED+157.42%INDA-5.34%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 181.28B
Dividend Yield
0.07%
Average Volume (3M)
64.95K
Price to Earnings (P/E)
54.1
Beta (1Y)
0.47
Revenue Growth
37.27%
EPS Growth
142.29%
Country
India
Employees
1,132
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Shilpa Medicare Limited Business Overview & Revenue Model

Company Description

Shilpa Medicare Limited, including its various subsidiaries, manufactures and distributes a range of active pharmaceutical ingredients (APIs), intermediate compounds, and finished drug formulations. Operating across India, the United States, Europe,...

Shilpa Medicare Limited Financial Statement Overview

Summary

Financial performance is strong overall, with steady multi‑year revenue growth, sharply improved profitability after a loss in 2023, and moderate leverage supported by a solid equity base, but persistently weak free cash flow and past margin volatility prevent a top‑tier score.

Income Statement

82Very Positive

Balance Sheet

78Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue18.42B15.39B12.86B11.53B10.43B11.40B
Gross Profit10.11B6.24B8.76B7.10B1.34B7.56B
EBITDA5.18B4.35B3.11B2.46B1.13B2.23B
Net Income3.32B2.43B782.93M318.74M-325.33M606.62M
Balance Sheet
Total Assets41.38B37.06B33.11B30.93B29.04B28.75B
Cash, Cash Equivalents and Short-Term Investments1.11B451.80M585.61M302.26M221.92M338.29M
Total Debt6.66B6.60B5.88B9.37B7.98B6.83B
Total Liabilities13.80B11.14B9.47B12.93B11.30B10.64B
Stockholders Equity27.58B25.91B23.72B18.09B17.83B18.22B
Cash Flow
Free Cash Flow0-754.00M-1.11B-492.22M-467.44M-2.27B
Operating Cash Flow02.95B1.32B1.35B1.80B1.05B
Investing Cash Flow0-3.27B-1.99B-1.67B-2.33B-2.85B
Financing Cash Flow0612.20M626.54M467.75M457.98M828.58M

Shilpa Medicare Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price917.00

Price Trends

50DMA966.18Negative
100DMA834.86Positive
200DMA618.75Positive

Market Momentum

MACD-0.67Negative
RSI45.43Neutral
STOCH49.74Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SHILPAMED, the sentiment is Negative. The current price of 917.00 is below the 20-day moving average (MA) of 921.32, below the 50-day MA of 966.18, and above the 200-day MA of 618.75, indicating a neutral trend. The MACD of -0.67 indicates Negative momentum. The RSI at 45.43 is Neutral, neither overbought nor oversold. The STOCH value of 49.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SHILPAMED.

Shilpa Medicare Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:SHILPAMED against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:STARIN:STAR77OutperformINR 90.65B14.68―0.51%11.28%55.18%
IN:CAPLIPOINTIN:CAPLIPOINT75OutperformINR 171.11B24.79―0.36%16.84%17.02%
IN:AKUMSIN:AKUMS73OutperformINR 112.80B30.16―0.42%17.50%14.74%
IN:SHILPAMEDIN:SHILPAMED71OutperformINR 179.35B54.08―0.07%37.27%142.29%
IN:APLLTDIN:APLLTD71OutperformINR 206.50B24.48―1.14%19.68%33.03%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:JUBLPHARMAIN:JUBLPHARMA49NeutralINR 151.92B57.43―0.52%18.30%-44.95%

* General Sector Average

Performance Comparison

0%50%100%150%IN:SHILPAMEDIN:AKUMSIN:APLLTDIN:CAPLIPOINTIN:JUBLPHARMAIN:STARDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:SHILPAMED and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:SHILPAMEDShilpa Medicare Limited917.00555.43153.61%
IN:AKUMSAkums Drugs and Pharmaceuticals Limited716.65294.1069.60%
IN:APLLTDAlembic Pharmaceuticals Limited1050.55157.5417.64%
IN:CAPLIPOINTCaplin Point Laboratories Limited2251.10327.9817.05%
IN:JUBLPHARMAJubilant Pharmova Limited953.80-148.44-13.47%
IN:STARStrides Pharma Science Ltd983.4526.732.79%

Shilpa Medicare Limited Corporate Events

Shilpa Medicare’s Jadcherla Unit Wins European GMP Nod

Oct 10, 2026

Shilpa Medicare Limited operates in the pharmaceutical industry, focusing on the manufacturing, testing and distribution of sterile injections and non-sterile tablet and capsule finished dosage forms. From its Unit 4 facility in Jadcherla, Telangana,...

Shilpa Medicare’s 39th AGM Confirms Clean Audit and Reviews Outlook

Sep 11, 2026

Shilpa Medicare Limited convened its 39th Annual General Meeting on September 11, 2026, via video conferencing and other audio-visual means from its registered office, adhering to guidelines issued by the Ministry of Corporate Affairs and SEBI. The m...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 19, 2026